SEC Tracker
Get the app

Provectus Biopharmaceuticals PVCT

Provectus Biopharmaceuticals reported $0 revenue and a $1.27 million net loss for Q3 2026.

Provectus Biopharmaceuticals (PVCT) filed a 10-Q with the SEC on Nov 10, 2026, 2:59 pm ET. Source: the filing on SEC EDGAR.

Form
10-Q
Filed
Importance
Notable
  1. Revenue: $0 for the three months ended Sep 30, 2026
  2. Net loss: $1.27 million for the three months ended Sep 30, 2026
  3. Cash and equivalents: $180,733 at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Going-concern warning repeated

“These circumstances raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that these unaudited condensed consolidated financial statements are issued.”
In the notes to the financial statements. Read it in the filing 10-Q on EDGAR

Also in the prior 10-Q (filed Aug 13, 2026). Prior report Prior on EDGAR

Quoted from the filing.

Get an email when Provectus Biopharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

No new risk factors or legal mentions.

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange vs prior 10-Q
Operating income and margin−$1.21M−$939K−29%
Net income−$1.27M−$983K−29%
Operating cash flow−$860K−$358K−140%
Cash$181K$1.16M−84%

Data on this page was fetched . The filing on SEC.gov is the record.